Phibro Animal Health (PAHC): Unprecedented Stock Surge And Strategic Acquisition
Phibro Animal Health (PAHC): Unprecedented Stock Surge And Strategic Acquisition
Phibro Animal Health Corporation (NASDAQ: PAHC) is on bullish trend during the current market trading today, marking a substantial increase of 29.41% to reach a valuation of $16.47. This upswing in PAHC stock follows an asset acquisition agreement.
在今天的市場交易中，Phibro動物健康公司（納斯達克股票代碼：PAHC）處於看漲趨勢，大幅上漲了29.41％，估值達到16.47美元。PAHC股票的上漲是在達成資產收購協議之後出現的。
Phibro Animal Health (PAHC) announced today that it and Zoetis Inc. (NYSE: ZTS) have entered into a final agreement. PAHC will pay $350 million, subject to normal closing adjustments, to acquire Zoetis' medicated feed additive (MFA) product array, certain water soluble products, and related assets.
Phibro Animal Health（PAHC）今天宣佈，它與Zoetis公司（紐約證券交易所代碼：ZTS）已簽訂最終協議。PAHC將支付3.5億美元，以收購Zoetis的藥用飼料添加劑（MFA）產品系列、某些水溶性產品和相關資產，但須視正常收盤調整而定。
It is anticipated that this deal would close in the second half of 2024. Zoetis and Phibro Animal Health both have a long history of commitment to the production animal health industry. The product assortment that was bought generated around $400 million in revenue in 2023 and consists of more than 37 product variants that are sold in almost 80 different countries.
預計這筆交易將在2024年下半年完成。Zoetis和Phibro Animal Health都對生產性動物健康行業有着悠久的承諾。購買的產品類別在2023年創造了約4億美元的收入，包括37多種產品變體，在近80個不同的國家銷售。
Moreover, the agreement encompasses six manufacturing facilities, with four situated in the U.S., one in Italy, and one in China. It is foreseen that over 300 Zoetis employees involved in manufacturing, distribution, and commercial operations will transition to Phibro Animal Health.
此外，該協議包括六個製造工廠，其中四個位於美國，一個位於意大利，一個位於中國。預計參與制造、分銷和商業運營的300多名Zoetis員工將過渡到Phibro Animal Health。
This transaction underscores Zoetis' disciplined approach to capital allocation, prioritizing investments in animal health, productivity, and sustainability solutions. Through this divestiture, Zoetis can redirect its livestock investments towards other solutions, encompassing vaccine, biologic, and genetic programs.
該交易凸顯了Zoetis嚴格的資本配置方針，優先投資於動物健康、生產力和可持續發展解決方案。通過這種剝離，Zoetis可以將其牲畜投資轉向其他解決方案，包括疫苗、生物和遺傳計劃。
Zoetis' robust portfolio of MFA and water soluble products spanning cattle, swine, and poultry will complement and broaden Phibro Animal Health's species and product portfolios, aiding customers in meeting the most stringent standards of animal welfare, disease prevention, and nutritional enhancement.
Zoetis強大的MFA和水溶性產品組合，涵蓋牛、豬和家禽，將補充和擴大Phibro Animal Health的物種和產品組合，幫助客戶滿足最嚴格的動物福利、疾病預防和營養增強標準。
If the acquisition's effects were taken into account, Phibro Animal Health would have had revenues of about $1.4 billion during the previous year. The acquisition is set to be primarily financed through debt, with Phibro Animal Health securing financing commitments from several key banking partners.
如果將此次收購的影響考慮在內，Phibro Animal Health上一年的收入將達到約14億美元。此次收購將主要通過債務融資，Phibro Animal Health將獲得多個主要銀行合作伙伴的融資承諾。
Over an extensive timeframe, Zoetis has established a valuable, top-tier, and dependable source of medicated feed additives worldwide. The asset acquisition will serve to enrich, diversify, and expand PAHC's global portfolio.
在很長的時間內，Zoetis已經在全球範圍內建立了寶貴、一流和可靠的藥用飼料添加劑來源。此次資產收購將有助於豐富、多元化和擴大PAHC的全球投資組合。
譯文內容由第三人軟體翻譯。